Korro's ANCHOR trial for KRRO-121 recruiting in Australia after first cohort dosed

Korro Bio's main activity of the week involved its RNA-editing program for hyperammonemia in urea cycle disorders (UCD).

• The ANCHOR trial (NCT07773246) for KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide, is listed as recruiting, with a single site active at Nucleus Network in Melbourne, Australia. The registry lists an estimated enrollment of 30 participants and ages 18 to 65 years.¹
• Korro said the first cohort of participants has been dosed in its Phase 1/2 clinical trial for KRRO-121, the Company's GalNAc-conjugated RNA-editing oligonucleotide (REO) in development for the potential treatment of hyperammonemia in patients with urea cycle disorders (UCDs) and patients with hepatic encephalopathy (HE).² The company said it administered a single dose of 2mg/kg to the first cohort of healthy volunteers.²
• The trial has two parts: Part 1 is a Phase 1 single ascending dose (SAD) study to be followed by a multiple ascending dose (MAD) study of KRRO-121 and placebo in healthy volunteers to evaluate safety, tolerability and pharmacokinetics (PK) in up to 50 participants², and Part 2 is a Phase 2 multiple dose study of KRRO-121 in up to 15 participants with UCD across all UCD genotypes to assess safety, tolerability, PK and clinical activity subject to regulatory approval.²
• Korro said Part 1 SAD, which started in September 2026, is enrolling up to 30 healthy volunteers across up to five cohorts, placebo-controlled at each dose level.²
• Korro said it is expected to start dosing in UCD patients in the first half of 2027 with an interim readout expected in the second half of 2027.²